يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas"', وقت الاستعلام: 1.08s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, León-Román J, Bermejo S, Bolufer M, Bestard O, Soler MJ Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CSUR National Unit of Expertise for Complex Glomerular Diseases of Spain, Barcelona, Spain. Iacoboni G Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Carpio C, Sánchez-Salinas M, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. García-Carro C Nephrology Department, San Carlos Clinical University Hospital, Madrid, Spain. Alonso-Martínez C Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Clinical Kidney Journal;17(3); https://doi.org/10.1093/ckj/sfae027Test; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI21%2F01292; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/AC22%2F00029; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/RD21%2F0005%2F0016; León-Román J, Iacoboni G, Bermejo S, Carpio C, Bolufer M, García-Carro C, et al. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies. Clin Kidney J. 2024 Mar;17(3):27.; https://hdl.handle.net/11351/11224Test

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Janeway KA Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts, USA. Gros L Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d'Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Schwartz S Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany. Daugherty C, Hill C BTG International Inc., Conshohocken, Pennsylvania, USA. Gallardo E Protherics Medicines Development Ltd., London, UK, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Pediatric Blood & Cancer;70(9); https://doi.org/10.1002/pbc.30506Test; Janeway KA, Gros L, Schwartz S, Daugherty C, Gallardo E, Hill C, et al. A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials. Pediatr Blood Cancer. 2023 Sep;70(9):e30506.; https://hdl.handle.net/11351/10260Test; 001017514700001

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Gordon LI, Karmali R, Kaplan JB Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. Popat R Department of Haematology, NIHR/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK. Burris HA 3rd Drug Development, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA. Ferrari S Dipartimento di Oncologia ed Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy. Carpio C Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Bosch F Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Oncotarget;14; https://doi.org/10.18632/oncotarget.28352Test; Gordon LI, Karmali R, Kaplan JB, Popat R, Burris HA 3rd, Ferrari S, et al. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget. 2023 Jan 26;14:57–70.; https://hdl.handle.net/11351/9094Test

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, de Koning C University Medical Center Utrecht, Utrecht, The Netherlands. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Tao W, Lacna A, van Veghel K University Medical Center Utrecht, Utrecht, The Netherlands. Horwitz ME Duke University Medical Center, Durham, NC, USA. Sanz G Hospital Universitario y Politécnico la Fe, València, Spain. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. Valcárcel D Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Bone Marrow Transplantation;56; https://doi.org/10.1038/s41409-021-01417-4Test; de Koning C, Tao W, Lacna A, van Veghel K, Horwitz ME, Sanz G, et al. Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. Bone Marrow Transplant. 2021 Nov;56:2826–2833.; https://hdl.handle.net/11351/6921Test; 000679018100001